Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03606200

Swiss Primary Ciliary Dyskinesia Registry

The Swiss Primary Ciliary Dyskinesia (PCD) Registry is a national patient registry that collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Ciliary Dyskinesia Abnormalities, Multiple Bronchial Diseases Bronchiectasis Cardiovascular Abnormalities Cardiovascular Diseases Ciliary Motility Disorders Ciliopathies Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dextrocardia Genetic Diseases, Inborn Heart Defects, Congenital Heart Diseases Kartagener Syndrome Otorhinolaryngologic Diseases Respiratory System Abnormalities Respiratory Tract Diseases Situs Inversus

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The Swiss Primary Ciliary Dyskinesia registry (CH-PCD) was founded in 2013 as a collaborative project between epidemiologists and adult and paediatric pulmonologists. It started as a pilot project in the canton of Bern and in 2014 was extended to include all Switzerland. The data centre of the SPCDR is located at the Institute of Social and Preventive Medicine at the University of Bern. It contributes data to the international PCD registry and other international studies such as the international PCD (iPCD) cohort.

Objectives of the CH-PCD:

The Swiss Primary Ciliary Dyskinesia Registry collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research. In particular, it aims to:

  • Identify all patients diagnosed with PCD in Switzerland.
  • Collect population based data (incidence, prevalence, time trends and regional trends).
  • Document diagnostic evaluations, treatments and participation in clinical trials.
  • Document the clinical course of PCD, quality of life, morbidity and mortality.
  • Establish a research platform for clinical, epidemiological and basic research.

Study design:

The CH-PCD is a patient registry. At baseline (inclusion of a patient to the registry), it collects retrospectively all available data since birth and it follows included patients throughout life until death or loss to follow up, collecting prospectively data at regular time intervals.

What data is collected:

The CH-PCD collects information on demographic characteristics (e.g. age, sex), diagnostic tests and clinical data about manifestations and management of the disease. It collects repeated follow-up data on growth, lung function, clinical manifestations from all affected organ systems, microbiology and imaging, lab results, therapeutic interventions (including surgery and physiotherapy) and hospitalisations. It also collects information on neonatal symptoms related to the disease and on the symptoms, that led to referral and PCD diagnosis.

Since 2020, the CH-PCD collects through questionnaire surveys patient-reported information on symptoms and lifestyle behaviours.

Study database:

The study database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.

How to participate:

Patients with PCD who would like to participate to the registry as well as physicians who treat patients with PCD should contact the CH-PCD to receive the study information and informed consent forms.

For further details, please contact: [email protected]

Funding:

The setting up of the CH-PCD (salaries, consumables and equipment) was funded by several Swiss funding bodies, including the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais and the Kantonalbernischer Hilfsbund.Research activities based on data included in the CH-PCD are funded by the Swiss National Science foundation (SNF 320030_173044, 320030B_192804 and PZ00P3_185923). The CH-PCD participated to the EU funded BEAT-PCD COST Action (BM1407) and participates to the BEAT-PCD clinical research collaboration supported by the European Respiratory Society.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with primary ciliary dyskinesia
  • Signed informed consent or assent

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Height

    Time frame: every 3 months up to 80 years

    Height z-scores calculated based on available national and international references

  2. BMI

    Time frame: every 3 months up to 80 years

    Body Mass Index (BMI) z-scores calculated based on available national and international references

  3. Lung function measurements

    Time frame: every 3 months up to 80 years

    Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values

  4. Measurement of nasal nitric oxide using breath analyzer

    Time frame: at study entry (in case patient is <5 years old at study entry, then the outcome will be assessed at age 5

    Results of nasal nitric oxide measurement, performed for diagnosis

  5. Cilia ultrastructure identified using electron microscopy analysis

    Time frame: at study entry

    Results of electron microscopy analysis of cilia, performed for diagnosis

  6. Ciliary beat frequency and beat pattern using video microscopy analysis

    Time frame: at study entry

    Results of video microscopy analysis of cilia, performed for diagnosis

  7. Microbiological culture of respiratory samples

    Time frame: every 3 months up to 80 years

    Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) expressed in a qualitative (growth or no growth of pathogens) or semiquantitative way (the type of sample depends on the age of the patient and the clinic the sample was collected).

  8. Antibiotic resistance of microbes isolated in microbiological cultures

    Time frame: every 3 months up to 80 years

    Information on antibiotic resistance of microbes isolated in microbiological cultures (see outcome 7) of respiratory samples, expressed either semiquantitatively or by the value of minimum inhibitory concentration.

  9. Chest computed tomography

    Time frame: every 3 months up to 80 years

    Radiological findings from chest computed tomography

  10. Sinus computed tomography

    Time frame: every 3 months up to 80 years

    Radiological findings from sinus computed tomography

  11. Vital status

    Time frame: every 3 months up to 80 years

    Vital status of patient: has the patient died or is he/she still alive and in case of death what was the cause?

  12. Clinical symptoms frequency

    Time frame: once a year up to 80 years

    Frequency of respiratory symptoms recorded with a patient or parent-reported questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Claudia E Kuehni, Prof

CONTACT

[email protected]

0041 316313507

Myrofora Goutaki, PD, MD-PhD

CONTACT

[email protected]

0041 316315973

Sponsors and collaborators

Lead sponsor

University of Bern

Other

Registry information

Acronym: CH-PCD

Important dates

Study start
2013
Primary completion
2080
Study completion
2080
First posted
Jul 30, 2018
Registry last updated
Nov 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.